Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Acta Pharmacol Sin ; 40(10): 1279-1291, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31000769

ABSTRACT

The pathogenesis of Alzheimer's disease (AD) is characterized by both accumulation of ß-amyloid (Aß) plaque and formation of neurofibrillary tangles in the brain. Recent evidence shows that autophagy activation may potently promote intracellular Aß clearance. Thus targeting autophagy becomes a promising strategy for discovery of drug leads against AD. In the present study, we established a platform to discover autophagy stimulator and screened the lab in-house FDA-approved drug library. We found that anti-parasitic drug nitazoxanide (NTZ) was an autophagy activator and could efficiently improve learning and memory impairments in APP/PS1 transgenic mice. In BV2 cells and primary cortical astrocytes, NTZ stimulated autophagy and promoted Aß clearance by inhibiting both PI3K/AKT/mTOR/ULK1 and NQO1/mTOR/ULK1 signaling pathways; NTZ treatment attenuated LPS-induced inflammation by inhibiting PI3K/AKT/IκB/NFκB signaling. In SH-SY5Y cells and primary cortical neurons, NTZ treatment restrained tau hyperphosphorylation through inhibition of PI3K/AKT/GSK3ß pathway. The beneficial effects and related signaling mechanisms from the in vitro studies were also observed in APP/PS1 transgenic mice following administration of NTZ (90 mg·kg-1·d-1, ig) for 100 days. Furthermore, NTZ administration decreased Aß level and senile plaque formation in the hippocampus and cerebral cortex of APP/PS1 transgenic mice, and improved learning and memory impairments in Morris water maze assay. In conclusion, our results highlight the potential of NTZ in the treatment of AD.


Subject(s)
Alzheimer Disease/drug therapy , Amyloid beta-Peptides/antagonists & inhibitors , Antiparasitic Agents/pharmacology , Disease Models, Animal , Learning/drug effects , Memory Disorders/drug therapy , Thiazoles/pharmacology , Alzheimer Disease/metabolism , Amyloid beta-Peptides/metabolism , Animals , Cells, Cultured , Humans , Memory Disorders/metabolism , Mice , Nitro Compounds
2.
Acta Pharmacol Sin ; 40(9): 1193-1204, 2019 Sep.
Article in English | MEDLINE | ID: mdl-30833709

ABSTRACT

Gluconeogenesis is a major source of hyperglycemia in patients with type 2 diabetes mellitus (T2DM), thus targeting gluconeogenesis to suppress glucose production is a promising strategy for anti-T2DM drug discovery. In our preliminary in vitro studies, we found that a small-molecule (E)-3-(2-(quinoline-4-yl)vinyl)-1H-indol-6-ol (QVO) inhibited the hepatic glucose production (HGP) in primary hepatocytes. We further revealed that QVO suppressed hepatic gluconeogenesis involving calmodulin-dependent protein kinase kinase ß- and liver kinase B1-adenosine monophosphate-activated protein kinase (AMPK) pathways as well as AMPK-independent mitochondrial function-related signaling pathway. To evaluate QVO's anti-T2DM activity in vivo, which was impeded by the complicated synthesis route of QVO with a low yield, we designed and synthesized 4-[2-(1H-indol-3-yl)vinyl]quinoline (IVQ) as a prodrug with easier synthesis route and higher yield. IVQ did not inhibit the HGP in primary hepatocytes in vitro. Pharmacokinetic studies demonstrated that IVQ was quickly converted to QVO in mice and rats following administration. In both db/db and ob/ob mice, oral administration of IVQ hydrochloride (IVQ-HCl) (23 and 46 mg/kg every day, for 5 weeks) ameliorated hyperglycemia, and suppressed hepatic gluconeogenesis and activated AMPK signaling pathway in the liver tissues. Furthermore, IVQ caused neither cardiovascular system dysfunction nor genotoxicity. The good druggability of IVQ has highlighted its potential in the treatment of T2DM and the prodrug design for anti-T2DM drug development.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Gluconeogenesis/drug effects , Hypoglycemic Agents/therapeutic use , Indoles/therapeutic use , Prodrugs/therapeutic use , Quinolines/therapeutic use , AMP-Activated Protein Kinases/metabolism , Animals , Diabetes Mellitus, Experimental/drug therapy , Electron Transport Complex I/antagonists & inhibitors , Electron Transport Complex III/antagonists & inhibitors , Enzyme Activators/therapeutic use , Enzyme Activators/toxicity , Enzyme Inhibitors/therapeutic use , Enzyme Inhibitors/toxicity , Glucose-6-Phosphatase/antagonists & inhibitors , Hepatocytes/drug effects , Hypoglycemic Agents/toxicity , Indoles/toxicity , Liver/drug effects , Male , Mice, Inbred C57BL , Mitochondria/drug effects , Phosphoenolpyruvate Carboxykinase (GTP)/antagonists & inhibitors , Prodrugs/toxicity , Quinolines/toxicity , Signal Transduction/drug effects
3.
Acta Pharmacol Sin ; 23(11): 1029-34, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12421481

ABSTRACT

AIM: To investigate the toxic effects of mid-pregnancy cocaine exposure on embryo-fetus. METHODS: A transplacental murine model of cocaine exposure on embryo-fetus mice was established, in which pregnant dams of comparable weight were assigned into three groups: cocaine with food ad lib (COC), saline and pair-fed with COC (SPF), and saline with food ad lib (SAL). From embryonic d 8 (E8) to E17, physiological variables of dams and offspring were recorded and concentrations of dopamine and serotonin in fetal striatum were examined. RESULTS: Compared with SAL dams, COC and SPF dams showed lower weight gain. But only COC fetuses demonstrated low brain weight and low striatum weight on E17, as well as small biparietal diameter (BPD) on postnatal d1 (P1). Surprisingly, low brain/body weight ratio was seen in COC offspring, which might reflect disproportionate growth delay in these fetuses. Neurotransmitter and histological analysis revealed high level of dopamine and serotonin in COC fetal striatum, as well as morphological alterations of liver. CONCLUSION: Mid-pregnancy cocaine exposure induces fetal growth delay in utero, especially disproportionate brain developmental retardation. Maternal undernutrition does not play a key role in fetal developmental retardation when exposed to cocaine in utero.


Subject(s)
Brain/drug effects , Cocaine/toxicity , Embryonic and Fetal Development/drug effects , Maternal-Fetal Exchange , Prenatal Exposure Delayed Effects , Animals , Animals, Newborn , Brain/embryology , Brain/metabolism , Corpus Striatum/embryology , Corpus Striatum/metabolism , Dopamine/metabolism , Female , Fetal Weight/drug effects , Mice , Organ Size/drug effects , Pregnancy , Serotonin/metabolism
4.
Sheng Li Xue Bao ; 54(4): 342-8, 2002 Aug 25.
Article in English | MEDLINE | ID: mdl-12195286

ABSTRACT

The aim of the experiments was to develop and characterize a murine model for investigating the effects of prenatal cocaine exposure on the mother and fetus. Pregnant mice were separated into three groups: group 1 was treated with cocaine HCl at 10 mg/kg twice daily (COC); group 2 was treated with saline at 10 ml/kg twice daily (SAL); and group 3 was pair-fed with the COC dams and was injected with saline following the same schedule (SPF) from embryonic day (E) 8 to 17. We utilized high-pressure liquid chromatography (HPLC) with UV detector and electrochemical detector to test the concentrations of cocaine, dopamine and serotonin, as well as HE staining to observe morphological alterations of liver and placenta. Though less food intake and lower weight gain were observed in COC and SPF groups but not in SAL dams, lower fetal body weight and brain weight were only seen in COC offspring. Pharmacological analysis revealed that cocaine was found in fetal plasma at 15 min following intraperitoneal administration on E17, accompanied with elevated concentrations of dopamine (DA) and serotonin (5-HT) in fetal brain. We also observed morphological changes in liver and placenta of cocaine-exposed fetuses. The present study indicates that pregnancy cocaine exposure can lead to maternal undernutrition and developmental abnormality of the fetal brain, liver and placenta. It is suggested that the developmental abnormality of the fetuses induced by cocaine is due to the toxicological effect of cocaine but not to maternal undernutrition.


Subject(s)
Cocaine/adverse effects , Disease Models, Animal , Fetus/drug effects , Maternal Exposure/adverse effects , Animals , Brain/metabolism , Brain/pathology , Cocaine/blood , Dopamine/metabolism , Female , Fetus/pathology , Liver/pathology , Malnutrition , Maternal Nutritional Physiological Phenomena , Mice , Mothers , Placenta/pathology , Pregnancy , Serotonin/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...